 Amneal Pharmaceuticals Inc NYSE: AMRX reports Q3 revenue of 529 million, a marginal increase of 2 YY, missing the consensus of 545.06 million. The increase was driven by Generic product launches and growth in Specialty products Rytary and Unithroid, partially offset by price erosion in its base business and slow demand at the start of the flu season. 